Inhibiting optic nerve degeneration to protect vision
Official title: Inhibition of Optic Nerve Degeneration
Funded at Gsno Therapeutics, INC. · NIH-11408481 · Data updated 2026-11-12
A patient-friendly look at a therapy that aims to protect retinal nerves in glaucoma and similar conditions by blocking a key enzyme.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gsno Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Shelton, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $303,035 |
| NIH project number | 1R43EY039156-01 |
| Project ID | NIH-11408481 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for optic nerve degeneration or currently experiencing early-stage optic neuropathies.
✕Less likely to help
Patients without optic nerve degeneration or advanced disease may not benefit from this specific approach.
What this research studies
This grant supports developing GTI-850, a drug that helps protect the optic nerve by boosting the body’s natural antioxidant defenses. The approach targets retinal ganglion cells to prevent degeneration and potential blindness. The study involves preclinical research to show how GTI-850 lowers oxidative stress and inflammation in eye tissues, with the goal of moving toward human studies. If successful, it could lead to new treatments that preserve sight for people with optic neuropathies.
Why it matters
Potential benefit: If successful, this therapy could slow or prevent vision loss for people with glaucoma and related optic nerve diseases.
How similar studies have gone: Other GTNOr inhibitors showing promise in reducing oxidative stress have produced encouraging preclinical results, but human data for GTI-850 is needed.
Where this research is happening
-
Gsno Therapeutics, INC.
Shelton, United States Active
Researchers
- Principal investigator: Bradley, Matthews — Gsno Therapeutics, INC.
- Study coordinator: Bradley, Matthews
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.